



UNIVERSITY OF LEEDS

This is a repository copy of *An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45*.

White Rose Research Online URL for this paper:
<http://eprints.whiterose.ac.uk/156412/>

Version: Accepted Version

Article:

Bjelic-Radusic, V, Cardoso, F, Cameron, D et al. (34 more authors) (2020) An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45. *Annals of Oncology*, 31 (2). pp. 283-288. ISSN 0923-7534

<https://doi.org/10.1016/j.annonc.2019.10.027>

© 2019 European Society for Medical Oncology. Published by Elsevier Ltd. This manuscript version is made available under the CC-BY-NC-ND 4.0 license <http://creativecommons.org/licenses/by-nc-nd/4.0/>.

Reuse

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can't change the article in any way or use it commercially. More information and the full terms of the licence here: <https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

Table 2. Patient characteristics Phase 3 study N=250

Status of disease	Number of patients	Percentage
newly diagnosed	137	54.8
no evidence of disease	82	32.8
recurrence	27	10.8
missing	4	1.6
Years since diagnosis		
less than 5 yrs	210	84.0
5 to 10 yrs	24	9.6
more than 10 yrs	13	5.2
missing data	3	1.2
Treatment status		
active treatment	186	74.4
no active treatment	62	24.8
missing	2	0.8
Menopausal status		
pre-menopausal	59	23.6
post-menopausal	150	60.0
treatment related menopause	28	11.2
unknown	11	4.4
missing	2	0.8
TNM		
T0	9	3.6
T1	99	39.6
T2	77	30.8
T3	22	8.8
T4	17	6.8
Tis	14	5.6
missing	12	4.8
N0	134	53.6
N1	76	30.4
N2	21	8.4
N3	7	2.8
missing	12	4.8
M0	212	84.8
M1	23	9.2
missing	15	6.0
Surgery		
breast conserving surgery	104	41.6
Oncoplastic breast conserving sur	13	5.2
simple mastectomy	49	19.6
mastectomy and	47	18.8

reconstruction		
missing	37	14.8
SN-biopsy	91	36.4
axillary dissection	92	36.8
no axillary operation	28	11.2
missing	39	15.6
unknown	11	4.4
Chemo- and target therapy		
Antracycline	95	62.1
Taxane	110	71.9
Carboplatin	6	3.9
Capecitabine	8	5.2
Vinorelbine	5	3.3
Gemcitabine	8	5.2
Ciclofusamide	99	64.7
others	35	22.9
Targettherapy		
Trastuzumab	52	82.5
Pertuzumab	16	25.4
T-DM1	1	1.6
Everolimus	3	4.8
Bevacizumab	2	3.2
Lapatinib	1	1.6
Oliparib	1	1.6
Palbociclib	2	3.2
Bisphophonate?	6	9.5
Hormonal therapy		
Aromatase inhibitors	65	50.8
Exemastane	26	20.3
Fulvestrant	7	5.5
GnRH analogue	8	6.3
Tamoxifen	65	50.8
others	9	7.0
Radiotherapy		
WBI	82	62.6
WBI with LAW	38	29.0
APBI	5	3.8
IORT	3	2.3
others	7	5.3

Key:

WBI- whole breast irradiation

WBI with LAW

APBI

IORT